In this issue:
- Breast cancer care and surgery in Australia and NZ
- Eliminating breast surgery in exceptional responders to neoadjuvant therapy
- Women’s experiences of age-related discontinuation of mammography screening
- Understanding of modifiable risk factors for breast cancer
- Lifestyle quality indices and female breast cancer risk
- Abemaciclib + endocrine therapy in high-risk early breast cancer
- Neratinib after adjuvant trastuzumab for HER2-positive breast cancer
- Trastuzumab biosimilar for ERBB2-positive early breast cancer
- Anthracycline- and taxanecontaining chemotherapy for early-stage operable breast cancer
- Trastuzumab deruxtecan in HER2-positive metastatic breast cancer
Please login below to download this issue (PDF)